Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia

Clinical Science

Volumn 108, Issue 2, 2005, Pages 113-119

  Christensen, Marina ^a   Ibsen, Hans ^a   Worck, René ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adrenaline; Angiotensin II; Haemodynamics; Hypoglycaemia; Insulin; Receptor blocker

Indexed keywords

ANGIOTENSIN; CATECHOLAMINE; EPROSARTAN; GLUCOSE; INSULIN; NORADRENALIN; PLACEBO; RENIN;

ADRENAL MEDULLA; ADRENALIN BLOOD LEVEL; ADRENERGIC STIMULATION; ADULT; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE;

ACRYLATES; ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CATECHOLAMINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPINEPHRINE; FOREARM; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; HYPOGLYCEMIA; IMIDAZOLES; INSULIN; MALE; NOREPINEPHRINE; THIOPHENES;

EID: 12944300998     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040094     Document Type: Article

References (30)

1. Brown, N. J. and Vaughan, D. E. (1998) Angiotensin-converting enzyme inhibitors. Circulation 97, 1411-1420
2. Unger, T. (2001) Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J. Renin Angiotensin Aldosterone Syst. 2 (Suppl. 2), 4-7
3. Hikosaka, M., Yuasa, F., Yuyama, R. et al. (2002) Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. J. Cardiovasc. Pharmacol. 40, 875-880
4. Heusser, K., Vitkovsky, J., Raasch, W., Schmieder, R. E. and Schobel, H. P. (2003) Elevation of sympathetic activity by eprosartan in young male subjects. Am. J. Hypertens. 16, 658-664
5. Bait, J. C., Mathy, M.-J., Pfaffendorf, M. and van Zwieten, P. A. (2001) Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J. Hypertens. 19, 2241-2250
6. Timmermans, P. B., Wong, P. C., Chiu, A. T. et al. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205-251
7. 1-receptor blockade and the sympathoadrenal response to hypoglycaemia in man. Am. J. Physiol. 272, E415-E421
8. Madsen, B. K., Holmer, P., Ibsen, H. and Christensen, N. J. (1992) The influence of captopril on the epinephrine response to insulin-induced hypoglycaemia in humans. The interaction between the renin-angiotensin system and the sympathetic nervous system. Am. J. Hypertens. 5, 361-365
9. Worck, R. H., Frandsen, E., Ibsen, H. and Pecersen, J. S. (1998) AT1 and AT2 receptor blockade and epinephrine release during insulin-induced hypoglycaemia. Hypertension 31, 384-390
10. Cox, S. L., Story, D. F. and Ziagras, J. (1996) Angiotensin II receptors involved in the enhancement of noradrenergic transmission in the caudal artery of the spontaneously hypertensive rat. Br. J. Pharmacol. 119, 965-975
11. Dendorfer, A., Raasch, W., Tempel, K. and Dominiak, P. (1998) Interactions between the renin-angioteusin system (RAS) and the sympathetic system. Basic Res. Cardiol. 93 (Suppl. 2), 24-29
12. Balt, J. C., Mathy, M.-J., Nap, A., Pfaffendorf, M. and van Zwieten, P. A. (2002) Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. J. Cardiovasc. Pharmacol. 40, 50-57
13. Carroll, M. F., Burge, M. R. and Schade, D. S. (2003) Severe hypoglycemia in adults. Rev. Endocr. Metab. Disord. 4, 149-157
14. Esler, M., Jennings, G., Korner, P. et al. (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11, 3-20
15. Appel, E., Bayer, P., Hajdu, P., Palm, P., Shofer, J. and Uilhein, M. (1981) Determination of plasma catecholamines by means of radioenzymatic labeling high pressure liquid Chromatographie separation. Naunyn Schmiedberg's Arch. Pharmacol. 315, 233-239
16. Klaniecki, T. S., Corder, C. N., McDonald, R. H. J. and Feldman, J. A. (1977) High-performance liquid chromatographic radioenzymatic essay for plasma catecholamines. J. Lab. Clin. Med. 90, 604-612
17. Poulsen, K. and Jørgensen, J. (1974) An easy radioimmunological microessay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J. Clin. Endocrinol. Metab. 39, 816-825
18. Millar, J. A., Leckie, B. J., Morton, J. J., Jordan, J. and Tree, M. (1980) A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin. Chim. Acta 101, 5-15
19. Kappelgaard, A. M., Nielson, M. D. and Giese, J. (1976) Measurement of angiotensin II in human plasma:technical modifications and practical experiences. Clin. Chim. Acta 67, 299-306
20. Guimaräes, S., Pinheiro, H., Tavares, P., Loio, A. and Moura, D. (2001) Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors. Arch. Pharmacol. 363, 509-514
21. Krum, H. (2001) Differentiation in the angiotensin II receptor 1 blocker class on autonomic function. Curr. Hypertension Rep. 3 (Suppl. 1), 17-23
22. Rupp, H. and Jäger, B. (2001) The Renin-angiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J. Clin. Basic Cardiol. 4, 47-51
23. Oparil, S. (2000) Newly emerging pharmacologic differences in angiotensin ii receptor blockers. Am. J. Hypertens. 13, 18S-24S
24. 1-receptor blockers: differences that matter. J. Hum. Hypertens. 16, S9-S16
25. Barki-Harrington, L., Luttrell, L. M. and Rockman, H. A. (2003) Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108, 1611-1618
26. Ohlstein, E. H., Brooks, D. P., Feuerstein, G. Z. and Ruffolo, Jr, R. R. (1997) Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 55, 244-251
27. Dendorfer, A., Raasch, W., Tempel, K. and Dominiak, P. (2002) Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat. J. Hypertens. 20, 1151-1156
28. Rongen, G. A., Lenders, J. W., Smits, P. and Floras, J. S. (2000) Comparison of two indices for forearm noradrenaline release in humans. Clin. Sci. 99, 363-369
29. Goldstein, D. S., Eisenhofer, G. and Kopin, I. J. (2003) Sources and significance of plasma levels of catechols and their metabolites in humans. J. Pharmacol. Exp. Ther. 305, 800-811
30. Baron, A. D. (1999) Vascular reactivity. Am. J. Cardiol. 84, 25J-27J